Choose language / Korean

Join Telegram
5 Future Scenarios For Post-Conflict Iran
Bull/Bear Index 50.0/100
macro ZeroHedge · 3h ago

5 Future Scenarios For Post-Conflict Iran

5 Future Scenarios For Post-Conflict Iran Authored by Christian Milord via The Epoch Times, There likely are more than five scenarios that Iranians could opt for as hostilities unwind, but the following five visions represent the paths Iran could take this year. Will 2026 onward become the Third Islamic Republic, following the first (1979-1989) and the second (1989-2026)? We can only speculate on the outcome of this third evolution, which might or might not be powered by clerics. First, in the fluid situation on the ground in Iran, There are many forces at work. When the dust clears, Iran might fall right back into the same rut it has traversed since 1979. Supreme Leader Mojtaba Khamenei might be at the top of the pyramid, while President Masoud Pezeshkian and members of the Assembly of Experts, Cabinet, Courts, Guardian Council, and Parliament will appear to remain loyal to the ide

Key takeaway

"5 Future Scenarios For Post-Conflict Iran" — BullBear's AI rates this story as a mixed, direction-neutral signal, with a market-impact score of 0 out of 100. 5 Future Scenarios For Post-Conflict Iran Authored by Christian Milord via The Epoch Times, There likely are more than five scenarios that Iranians could opt for as hostilities unwind, but the following five visions represent the paths Iran could take this year. Will 2026 onward become the Third Islamic Republic, following the first (1979-1989) and the second (1989-2026)? We can only speculate on the outcome of this third evolution, which might or might not be powered by clerics. First, in the fluid situation on the ground in Iran, There are many forces at work. When the dust clears, Iran might fall right back into the same rut it has traversed since 1979. Supreme Leader Mojtaba Khamenei might be at the top of the pyramid, while President Masoud Pezeshkian and members of the Assembly of Experts, Cabinet, Courts, Guardian Council, and Parliament will appear to remain loyal to the ide That score reflects how strongly the story is likely to move Bitcoin, US equities, the dollar, and gold, and near-duplicate coverage of the same event is clustered so only the representative article is scored. BullBear analyzes hundreds of market stories a day this way, turning each into a structured bullish, bearish, or mixed read rather than a raw headline, so the signal can be compared across sources and over time. Reported by ZeroHedge on June 09, 2026. The bullish and bearish evidence behind this assessment, plus a 24-hour price-move check that verifies the call against what actually happened, are all tracked publicly on BullBear.news.

Get the next 8/10 catalyst

Telegram alerts when our AI scores a story 8+/10 (~1-3 per day, no spam). Verified 30d hit rate 58.1%.

Join Telegram channel

📡 Tomorrow's Watch

Related news

Fed to hold rates this year, cut calls fade as war inflation persists, economists say: Reuters poll  Yahoo! Finance Canada

#macro

Dow futures climb 125 points: 5 things to know before Wall Street opens  TradingView

#macro

Goldman Hikes Obesity Drug Market Forecast As Oral GLP-1s Go Mass Market The global weight-loss drug market is now expected to reach $114 billion by 2030, up from Goldman's prior $101 billion forecast, as analysts cite faster adoption of oral obesity pills, stronger demand outside the U.S., and improved affordability that is expanding the patient pool. Goldman analysts led by Asad Haider and James Quigley laid out four main drivers behind the upgraded 2030 anti-obesity drug TAM forecast (previous forecast made in Dec. 2025): 1. Higher oral vs. injectable share and a higher oral TAM. With oral NBRx (new-to-brand) prescriptions (a leading indicator) now 40-50% following the strong launch of Novo's Wegovy pill, we now expect orals to represent 40% ($46bn) of the 2030 global revenue TAM (vs. 35%/$35bn prior). 2. Shifting sales mix within orals. We balance our share splits with Novo's Wegovy pill now 38% (vs. 16% prior), LLY's Foundayo now 48% (54% prior) and "other" now 14% (vs. 30% prior). We now forecast Wegovy peak global sales of $17.4bn (vs. prior $8bn) and Foundayo 2030 sales of $22bn (vs. prior $19bn). 3. Increased OUS penetration and a higher OUS TAM. Per stronger-than-expected OUS ramp for LLY's Mounjaro, we now forecast 2030 total OUS obesity sales of $48bn vs. $39bn prior, driving most of the higher 2030 Global TAM from $101bn to $114bn. 4. Updated pricing assumptions across channels. We lower pricing assumptions in the US DTC channel by 20% (to now $287 vs. prior $355) driven by lower prices across the board and higher oral mix shift. Haider expects El

#macro

Asian currencies steady as US inflation data and less dovish Fed outlook keep dollar supported  VT Markets

#macro

After jobs report shock, US CPI data to test AI rally; here's how to trade around it  TradingView

#macro

Hotter US inflation numbers could further bolster Fed hike bets – Preview  FXStreet

#macro